Neimeth PLC

Last updated

NEIMETH International Pharmaceuticals PLC is a publicly listed pharmaceutical company founded in 1997 and headquartered in Lagos. It was established by a former managing director of Pfizer Products of Nigeria to acquire some of the trading assets of Pfizer International in Nigeria. [1]

Contents

History

Pfizer in Nigeria

Pfizer began operations in Nigeria in 1957 importing its branded products such as Terramycin into the country. In 1962, it opened a factory at Aba, the first pharmaceutical factory in British West Africa. The Civil war in Nigeria affected production at Pfizer's plant at Aba which caused the firm to commit new investment to build a new plant at Oregun, Lagos. The new factory expanded Pfizer's product offerings to include inject-able drugs. [1]

In the 1990s, the firm faced increased competition from imported generic products from Asia and those manufactured within the country. While, the firm generated majority of its sales through relationships with pharmacists and hospitals, the rise in OTC consumption and importation of generics shifted the firm's focus away from business to business sales of prescription drugs and towards OTCs. The firm increased production of OTC drugs and sales to drug stores and other over the counter retailers. [1]

Neimeth

In 1997, the parent company's global re-positioning away from OTC drugs led to a management buyout of majority shares. The new firm was named Neimeth International Pharmaceuticals, in honor of a Pfizer executive who provided support to the Nigerian operation. [1] At inception, Neimeth manufactured drugs licensed from Pfizer International, [2] in 2009, Neimeth's in-house research had yielded product that account for 30% of its revenues. [3]

In the middle of 2010s, Neimeth went through a period of losses, at one time, it lost an entire stock of raw materials in a fire incident. [4]

Products

Neimeth's in-house research and development created an herbal remedy for sickle cell crisis management called Ciklavit, with Cajanus cajan as an active ingredient. [5] The drug is one of the offering from its Neimeth Product Group, a strategic business unit of the firm that also markets generic offerings such as Normoretic and flexodene.

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

Nigerian Breweries Plc, is the largest brewing company in Nigeria. It serves the Nigerian market and West Africa.

<span class="mw-page-title-main">Parke-Davis</span> Pfizer subsidiary

Parke-Davis is a subsidiary of the pharmaceutical company Pfizer. Although Parke, Davis & Co. is no longer an independent corporation, it was once America's oldest and largest drug maker, and played an important role in medical history. In 1970 Parke-Davis was acquired by Warner-Lambert, which in turn was acquired by Pfizer in 2000.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

The United Africa Company of Nigeria is a Nigerian publicly listed company based in Lagos. Its areas of operation include manufacturing, services, logistics and warehousing, agricultural and real estate. UACN's food operations include UAC Franchising, UAC Restaurants and UAC Dairies. It also has equity stake in UACN Property Development Company, a quoted firm, CAP Plc, makers of Dulux paints and Portland Paints, manufacturers of Sandtex paints.

Kaye Scholer was a law firm founded in 1917 by Benjamin Kaye and Jacob Scholer. The firm had more than 450 attorneys in nine offices located in the cities of Chicago, Frankfurt, London, Los Angeles, New York City (headquarters), Shanghai, Palo Alto, Washington, D.C., and West Palm Beach.

<span class="mw-page-title-main">Hospira</span>

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Nicosan, also known as Hemoxin, Niprisan, or Nix-0699, is a phytochemical which was studied in sickle-cell disease (SCD). As of 2017 it does not appear to be commercially available, as the only manufacturer, which was in Nigeria, has stopped producing it due to financial problems.

<span class="mw-page-title-main">China Nepstar</span>

China Nepstar Chain Drugstore Ltd., which conducts business as China Nepstar, is China's largest retail drugstore chain, based on the number of directly operated stores. It is headquartered in Nanshan District, Shenzhen.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Unilever Nigeria Plc is a publicly listed company with trading and manufacturing interest in the consumer goods market. In 2014, it was listed among the top 20 most valuable companies quoted on the Nigerian Stock Exchange. Unilever Nigeria PLC is a subsidiary of Unilever Overseas Holding B.V.

Nestle Nigeria Plc is a publicly listed food and beverage specialty company headquartered in Lagos. It's mostly owned by a holding company based in Switzerland and have ties to the company Tolaram Group. The company was founded in 1961 and conducted trading under the name of Nestle Products Nigeria Limited. It has its main factory in Agbara Industrial Estate, Ogun State. The firm manufactures breakfast cereal, baby food products, food seasoning and hydrolyzed plant protein mix.

The National Institute for Pharmaceutical Research and Development (NIPRD) is a Nigerian institution charged with developing drugs, biological products, and pharmaceutical raw materials, conducting quality-assurance tests, research for locally manufactured medicines and constituting guidelines for their production. Founded in 1987, it was a parastatal under the Federal Ministry of Science and Technology. In 2001, it was moved to Federal Ministry of Health.

References

  1. 1 2 3 4 Utomi, Patrick O. (1998). Managing uncertainty: competition and strategy in emerging economies. Ibadan: Spectrum Books Ltd. pp. 448–453. ISBN   978-9780290023. OCLC   40592019.
  2. "Strategic Report on Neimeth Pharmaceuticals PLC" (Document). Meristem Securities. 2006.
  3. "Investment Policy Review Nigeria" (PDF). United Nations Conference on Trade and Development. p. 2009.
  4. "Neimeth Pharmaceuticals sticks to loss position". Brand Spur. 2018-01-29. Retrieved 2018-10-12.
  5. Ameh, Sunday J.; Tarfa, Florence D.; Ebeshi, Benjamin U. (2012). "Traditional Herbal Management of Sickle Cell Anemia: Lessons from Nigeria". Anemia. 2012: 607436. doi: 10.1155/2012/607436 . ISSN   2090-1267. PMC   3502758 . PMID   23198140.